M&A, new modalities, and COVID-19 have all changed the way drug sponsors work with their third-party manufacturers, according to delegates from Samsung Biologics, Catalent, and AGC Biologics.
The BioProcess Insider Expression Platform (BIEP) podcast is back, with an in-depth look at the evolving relationships between biopharma and their contract development and manufacturing organization (CDMO) partners.
Recorded live from EBD’s BIO Europe Spring event last month, BioProcess Insider discussed the changing dynamic and reliance drug sponsors have with their CDMOs with:
Kevin Sharp, VP, Head of Global Sales Strategic Operations, Samsung Biologics
Barbara Sambuco, VP Operations, Drug Product, Biotherapeutics, Catalent
Christoph Winterhalter, SVP, Business Development, AGC Biologics
You can listen to the full panel via Spotify, Apple iTunes, Google Podcasts, and other platforms, or listen directly below:
You May Also Like
schedl_b_and_w.jpg?width=100&auto=webp&quality=80&disable=upscale "Picture of Dan Stanton")
schedl_b_and_w.jpg?width=400&auto=webp&quality=80&disable=upscale "Dan Stanton")
